Processa Pharmaceuticals, Inc.
PCSA evidence brief
What we can confirm
- Market Cap:
- $5.8M
What it means
What to watch
Prepared research question
What matters most for PCSA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PCSA
Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing next-generation cancer therapies and other drug candidates using a proprietary Regulatory Science Approach, with a recent acquisition and financing to advance its lead program VT-7208.
Key risk: No product revenue
Market Cap
$5.8M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing next-generation cancer therapies and other drug candidates using a proprietary Regulatory Science Approach, with a recent acquisition and financing to advance its lead program VT-7208.
- Processa is a clinical-stage biopharmaceutical company developing a pipeline of Next Generation Cancer therapies and two non-oncology drugs [sec_mda · as of 2026-05-07].
- The company has an accumulated deficit of $107.4 million as of June 30, 2026, and has not generated any product revenue [sec_mda · as of 2026-08-14].
- During the six months ended June 30, 2026, Processa generated a net loss of $6.6 million [sec_mda · as of 2026-08-14].
- In 2026, the company raised approximately $200 million in gross proceeds through a private placement financing concurrent with the acquisition of Vidya, expected to support advancement of VT-7208 [sec_mda · as of 2026-08-14].
- As of June 30, 2026, management believes current cash will be sufficient for at least 12 months, removing the prior going concern doubt [sec_mda · as of 2026-08-14].
What works
- The company's Regulatory Science Approach aims to improve the therapeutic effect and reduce toxicity of existing cancer drugs, potentially increasing the likelihood of regulatory approval [sec_mda · as of 2026-05-07].
- Processa raised approximately $200 million in a private placement financing concurrent with the acquisition of Vidya, providing substantial capital to advance VT-7208 through multiple clinical milestones [sec_mda · as of 2026-08-14].
- Management believes current cash will be sufficient for at least 12 months as of June 30, 2026, removing the prior substantial doubt about going concern [sec_mda · as of 2026-08-14].
What to weigh
- Processa has an accumulated deficit of $107.4 million as of June 30, 2026, and has not generated any product revenue to date [sec_mda · as of 2026-08-14].
- The company has a history of net losses, with a net loss of $6.6 million during the six months ended June 30, 2026 [sec_mda · as of 2026-08-14].
- The company faces risks related to its ability to defend intellectual property, remain listed on Nasdaq, and continue as a going concern [sec_mda · as of 2026-08-14].
From the filings
Quoted directly from source documents.
Accumulated deficit as of June 30, 2026
“accumulated deficit of $107.4 million at June 30, 2026”
SEC MD&A · August 14, 2026
Net loss for six months ended June 30, 2026
“During the six months ended June 30, 2026, we generated a net loss of $6.6 million”
SEC MD&A · August 14, 2026
Going concern doubt removed as of June 30, 2026
“will be sufficient to satisfy our cash requirements over the next 12 months and beyond. This represents a material change from what we reported in our 2025 Form 10-K that disclosed substantial doubt of our ability to continue as a going concern”
SEC MD&A · August 14, 2026
Private placement financing of ~$200 million concurrent with Vidya acquisition
“Concurrent with the acquisition of Vidya, we entered into a definitive agreement for a private placement financing to raise approximately $200 million in gross proceeds”
SEC MD&A · August 14, 2026
Risks & what to watch (4)›
Key risks
- No product revenue — None of the company's drug candidates have been approved for sale, and it has not generated any product revenue [sec_mda · as of 2026-08-14].
- History of losses — Processa has incurred losses since inception, with an accumulated deficit of $107.4 million as of June 30, 2026 [sec_mda · as of 2026-08-14].
- Capital needs — The company may need to raise additional capital to fund operations beyond the next 12 months [sec_mda · as of 2026-08-14].
- Intellectual property risks — The company faces exposure to third-party claims and challenges to its patents and intellectual property rights [sec_mda · as of 2026-08-14].
What to watch
- Progress of the NGC-Cap Phase 2 advanced or metastatic breast cancer trial, including preliminary safety-efficacy data [sec_mda · as of 2025-11-06].
- Advancement of VT-7208 through clinical milestones, supported by the $200 million private placement financing [sec_mda · as of 2026-08-14].
- Enrollment and data from the Phase 2 study of PCS6422 [news · published 2025-07-01].
- Potential licensing or partnership developments for PCS12852, as Intact Therapeutics has an exclusive option to license [news · published 2025-07-01].
Sources: News · SEC MD&A · Generated September 24, 2026 · How we verify sources →
Run Processa Pharmaceuticals, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Processa Pharmaceuticals, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
10
Total value held
$448K
| Holder | Shares | Value |
|---|---|---|
| connective capital management, llc | 70,736 | $179K |
| stonepine capital management, llc | 55,000 | $139K |
| geode capital management, llc | 24,908 | $63K |
| vanguard capital management llc | 12,729 | $32K |
| vanguard fiduciary trust co | 10,857 | $27K |
| ubs group ag | 2,531 | $6K |
| tower research capital llc (trc) | 918 | $2K |
| citigroup inc | 14 | $35 |
| jones financial companies lllp | 7 | $17 |
| wells fargo & company/mn | 6 | $15 |
Short Interest
as of May 22, 2026- % of float
- 5.7%
- Days to cover
- 1.8
- Shares short
- 135,440
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PCSA short interestGovernance
Frequently asked questions
What is the AI investment thesis for Processa Pharmaceuticals, Inc.?
Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing next-generation cancer therapies and other drug candidates using a proprietary Regulatory Science Approach, with a recent acquisition and financing to advance its lead program VT-7208.
Who is the CEO of Processa Pharmaceuticals, Inc.?
Mr. George K. Ng Esq., J.D. is the chief executive officer of Processa Pharmaceuticals, Inc. (PCSA).
Where is Processa Pharmaceuticals, Inc. headquartered?
Processa Pharmaceuticals, Inc. (PCSA) is headquartered in Vero Beach, FL, United States.
What therapeutic areas does Processa Pharmaceuticals, Inc. focus on?
Processa Pharmaceuticals, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.